Quick Answer: Curiox Biosystems has expanded its senior commercial team and formed a Strategic Advisory Board to push its C-FREE technology into more flow cytometry labs. Centrifuge-free sample preparation removes the spin-down pelleting step from cell washing. The goal is less cell loss, less variability between operators, and easier automation. Whether it fits your lab depends on how it performs on your own samples.
Every flow cytometry lab has a version of the same frustration: a cell pellet that doesn't come back the way it went in. Some cells stick to the tube wall, some get sheared, and the count you get at the cytometer depends partly on who ran the spin. On October 30, 2026, Curiox Biosystems announced moves aimed at fixing that gap at the commercial level. Here's what the announcement actually says, what centrifuge-free prep changes, and how to test it without betting your panel on a press release.
What Curiox Actually Announced
According to News-Medical, Curiox Biosystems Inc. is a provider of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows. The company announced two things: an expansion of its senior commercial team and the formation of a Strategic Advisory Board (SAB).
Read that carefully. It's a commercial and governance announcement. It's not a data release. The summary doesn't include throughput numbers, cell recovery figures, or validation studies, and it doesn't name the new hires or advisors. That doesn't make the move meaningless. A company hiring senior commercial staff usually signals it's moving from early adopters toward broader lab adoption. But it means the technical claims still need to be checked against your own data.
Why Centrifugation Is the Step Everyone Tolerates
Conventional cell washing follows a familiar pattern: add buffer, spin the sample, aspirate the supernatant, resuspend the pellet. Repeat as needed. The spin concentrates cells so you can remove unbound antibody or the medium they were grown in. It works, which is why most labs never question it.
The problem is what happens between the spin and the resuspension. Pellets can be loose, and a careless aspiration can take cells with it. Resuspension requires shear, and aggressive pipetting damages fragile populations. Each wash cycle adds another chance to lose material.
Here's the counter-intuitive part. The popular advice is to wash more to get a cleaner sample. In practice, extra wash cycles often hurt more than they help once you're working with limited input. If you're hunting a rare population at 0.1% of events, losing a fraction of your cells in each wash can shift that frequency enough to change your conclusions. Fewer, better-controlled steps are usually the safer path, and that's the logic behind eliminating the spin rather than optimizing it.
This next part matters more than it looks. Centrifuge-free approaches don't remove the need to wash. They change how the wash happens, which changes where cells can be lost and how much your results depend on the operator's technique.
What "Centrifuge-Free" Changes in the Workflow
Think of the conventional and centrifuge-free workflows as two different sequences of handling steps. The chemistry of antibody staining stays the same. The physical handling of the cells is what differs.
A conventional wash generally runs like this:
- Transfer cells to a tube and add wash buffer.
- Centrifuge at a set speed and time, then wait for the pellet to form.
- Aspirate the supernatant without disturbing the pellet.
- Resuspend by gentle pipetting or vortexing.
- Repeat for each wash, then proceed to staining.
A centrifuge-free workflow replaces the pelleting and aspiration sequence with a buffer exchange that keeps cells in place or moves them across a defined process. Because no pellet forms, there's nothing to lose at the aspiration step. The practical benefits are straightforward: fewer manual transfers, less dependence on how a technician handles a loose pellet, and a process that's easier to map onto liquid handlers. That last point is why the automation claim in the announcement matters. A protocol that depends on a human judging a pellet is hard to automate reliably.
The tradeoff is that you're now validating a new handling step. Your existing SOPs, your reference data, and your gating strategy were built around the old process.
Centrifuge-Free vs. Conventional Washing: A Practical Comparison
The table below is a qualitative framework for deciding whether to pilot a centrifuge-free workflow. It's built from the mechanics above, not from measured performance of any specific product, so use it to frame your own tests.
| Factor | Conventional centrifuge wash | Centrifuge-free wash |
|---|---|---|
| Pellet-related loss risk | Present at each aspiration step | No pellet step to lose |
| Operator dependence | High; pellet judgment varies by person | Lower; steps are more defined |
| Automation compatibility | Harder; relies on pellet visualization | Designed for automated workflows, per the company |
| Validation burden | Low; long-established SOPs | Higher; requires bridging against existing data |
Notice that the validation row is the one labs underestimate. A workflow can be easier to run and still require weeks of comparison before you trust its frequencies.
Why Commercial Leadership Matters for a Tool Like This
Adoption of a sample prep technology depends less on the bench chemistry than most scientists assume. A lab has to learn the protocol, understand the failure modes, and get the data to survive a reviewer's questions. That takes application scientists, distributors who can support installs, and clear documentation.
That's the context for the commercial expansion. Senior commercial leaders typically set the strategy for which segments to target, which partnerships to pursue, and how to fund field support. The Strategic Advisory Board typically provides outside input on technical direction and market needs. In flow cytometry, an advisory group drawn from experienced core facility directors or translational researchers can be valuable because they know which validation hurdles actually stop adoption.
That said, an advisory board is advisory. It doesn't validate the technology. If you're evaluating the company, ask who sits on the board and what evidence they've reviewed, not just whether the board exists.
The Risks, Limits, and Things to Check First
Several caveats apply, and a responsible evaluation should address them before any purchase.
Panel compatibility. Some surface markers and fluorochromes are sensitive to buffer composition and incubation changes. A wash that works well for one panel may affect a dim marker on another.
Reporting and reproducibility. If you publish or submit data, you'll need to document the workflow clearly. The MIFlowCyt standard, developed by the International Society for Advancement of Cytometry (ISAC) and its collaborators, provides a framework for reporting flow cytometry experiments. Your new prep step should be described well enough that another lab could reproduce it.
Regulatory context. If your work touches clinical or diagnostic use, check whether the product is labeled for research use only or is under a regulatory pathway you need. Don't assume that a workflow suitable for discovery research is suitable for a clinical assay.
Cell type specificity. Primary cells, fragile subsets, and cells from patients with low counts behave differently from cell lines. Test with the sample types you actually run.
Most people stop here, and that's a mistake. The question isn't whether centrifuge-free prep is good in general. It's whether it's good for your cells, your markers, and your throughput.
How to Test a Centrifuge-Free Workflow Without Risking Your Study
A small, well-designed bridging study is more useful than a vendor demo. Here's a practical sequence.
- Choose three to five representative samples, including one with a known rare population.
- Split each sample and process half by your current centrifuge-based method and half by the new method, on the same day.
- Count viable cells before and after the wash, using a counting method you trust, such as an automated counter with viability dye or counting beads.
- Stain both arms with an identical panel and compare population frequencies, not just MFI.
- Set an acceptance threshold before you run the test, then decide based on the data.
Here's where it gets interesting. Many labs judge the new method by whether the plots look similar. Look at the numbers that matter for your question. If a rare population shifts by a few tenths of a percent, that may be the whole story.
Frequently Asked Questions
What is centrifuge-free sample preparation?
Centrifuge-free sample preparation is a method for washing and buffer-exchanging cells without the spin-down pelleting step used in conventional protocols. It aims to reduce cell loss and operator-dependent variability. Curiox Biosystems markets its C-FREE technology for flow cytometry workflows. Whether it suits your samples depends on validation against your existing method.
How do you switch to centrifuge-free sample prep without ruining your data?
Run a bridging study with the old and new methods on the same samples at the same time. Compare population frequencies and viable cell counts, using acceptance criteria you set in advance. Keep your panel and gating unchanged during the comparison so any difference comes from the prep step.
Why does centrifugation cause cell loss in flow cytometry?
Pellets are often loose, and aspiration can remove cells along with the supernatant. Resuspension adds shear and can damage fragile cells. Each wash cycle adds another opportunity for loss, which matters most when you're working with limited or rare cell populations.
When does centrifuge-free sample preparation make more sense than a conventional wash?
It makes the most sense when you have high sample-to-sample variability, rare populations where cell loss changes results, or a plan to automate sample prep. It makes less sense if your current SOP is well validated and your throughput is low. Test it against your own samples before committing.
Test It on Your Own Samples
The most useful takeaway is simple: treat centrifuge-free prep as a hypothesis about your workflow, not a conclusion. Pick one assay where pellet loss or operator variability has bothered you, and run a side-by-side comparison this month. Record the population frequencies and viable counts, then decide with the numbers. Pass this to whoever runs your cytometer and ask them which step they'd want to test first.